



PRESS RELEASE

**Bengaluru, India; April 12, 2021:**

## **'Inauguration of COVID-19 Vaccination Centre at Syngene International Limited, Biocon Group of Companies'**

The Biocon Group of Companies today inaugurated a Vaccination Centre at the Bengaluru campus of Syngene International Limited as part of the nationwide drive for mass vaccination of individuals above 45 years of age to protect them against COVID-19. The group has started vaccinating all eligible employees in keeping with its commitment to ensure the health and safety of its workforce. As a responsible corporate citizen, it will also work closely and in partnership with the Government of Karnataka to create awareness and offer this service to all people who are eligible in the Electronic City area of Bengaluru. The Biocon Group is the 1<sup>st</sup> Corporate entity to kickstart this vaccination centre in Bengaluru.

The centre was inaugurated in the august presence of Health Officials and Dignitaries from the District Administration and the Biocon Group: Shri Manjunath J – District Commissioner, Bengaluru; Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon; Dr Mahesh Bhalgat, Chief Operating Officer, Syngene; Dr Srinivas G- District Health Officer, Bengaluru; Dr Syed Sirajuddin- RCHO & District Immunization Officer, Bengaluru; Dr Manohar -District Surveillance Officer, Bengaluru; Shri Dinesh P - Tehsildar, Anekal Taluk; Dr Vinay Kumar M - Taluk Officer, Anekal; Dr Anil, Sr. General Manager, Syngene and Ms. Rama N S, CEO, Electronic City Industrial Township Authority (ELCITA).

Biocon Group of Companies in its battle against COVID-19 has been constantly striving to provide a safe and conducive workplace to its employees and address the unmet needs of patients, partners and the public at large. It has enabled testing facilities and kits, therapeutics and support systems earlier. Vaccination is a powerful armour against this deadly infection and getting vaccinated and following all COVID-19 appropriate behaviours is the need of the hour. This initiative is in continuation to the Group's ongoing efforts to support the government and the community in the fight against COVID-19 pandemic.

**Shri Manjunath J, I.A.S., District Commissioner, Bengaluru,** said, *"We have started vaccination drive at workplaces, starting with the Biocon Group situated in the Electronic City. Kiran Mazumdar-Shaw has always been a source of immense support and strength in our COVID containment drive. I express my sincere gratitude to her for enabling us with the vaccination drive at this critical time. Once, all the eligible employees of Biocon Group and their families are vaccinated, this facility will be open to support other companies too. I urge everyone above 45+ age group to make the most of this opportunity and get vaccinated."*

**Kiran Mazumdar Shaw, Executive Chairperson, Biocon,** said, *"We feel proud and privileged that the Government of Karnataka has given us the first permission as a corporate to initiate vaccination drive for our employees. We will be working closely and in partnership with the government to roll out this vaccination drive, create awareness and offer this service to all"*



people who are eligible in the Electronic City area of Bengaluru, apart from our own employees.”

**Dr Mahesh Bhalgat, Chief Operating Officer, Syngene International Limited,** said, *“The Biocon Group is committed to ensuring the safety and wellbeing of its workforce. Since July 2020, we are proactively testing our employees to identify infection cases and immediately quarantine them and provide necessary medical support. We are now happy to provide free vaccination for our employees and their family. This is an extension of our commitment to safeguarding our employees' health as well as a reflection of our commitment to support the government's efforts to combat and contain the pandemic.”*

**Ms. Rama N S, CEO, Electronic City Industrial Township Authority (ELCITA),** said, *“This is a professionally managed facility and I recommend all eligible candidates from Electronic City to get vaccinated here. While initially Biocon Group employees will be benefitted with this vaccination drive, the facility will be extended eventually to include other industries and people living around this area. Earlier also, this facility had organized RT-PCR testing for other companies very well.”*

Biocon Group of Companies is thankful to the District Administration and the Health Authorities of Bengaluru for granting the license to Syngene Clinical Development Centre, enabling the vaccination drive for COVID-19. Biocon Group of Companies comprises of Biocon Limited, Biocon Biologics Limited and Syngene International Limited.

At a very early stage of the pandemic, the Biocon Group, had set up a state-of-the-art RT-PCR testing centre to support hospitals in Karnataka and to expand the state’s testing capacity. The Group is also doing proactive testing of all its onsite employees at Syngene’s facility. This has helped maintain a low positivity rate on campus by identifying positive cases early on and providing immediate medical support. Till date the centre has conducted around 1.85 lac testing of which about 90% was conducted free of charge for the community and Biocon Group employees.

As a part of its commitment to address the novel coronavirus pandemic in India, the Biocon Group is also offering a comprehensive portfolio of products for treating mild to severely ill COVID-19 patients. We have introduced ARAFLU® (Favipiravir) in addition to Cytosorb® and ALZUMAB-L™, and Syngene is manufacturing Remdesivir under a voluntary licensing agreement with Gilead.

Since the outbreak of COVID-19, Biocon Group of Companies are taking all required measures to ensure health and safety of its employees. The organization introduced shift working and working from home, colour-coded zones across its facilities, additional number of company transport to reduce the number of travellers per vehicle etc. In addition, the company is monitoring body temperature of all its employees working at the site, providing hand sanitizers and enabling the employees with all COVID-related updates regularly. Now with the vaccination drive, the organization is ensuring safety of its employees, their family members as well as the community at large.



For more Information:

Riddhima Jaitly, Biocon Group, +91 - 9742197514

[Riddhima.jaitly@biocon.com](mailto:Riddhima.jaitly@biocon.com)

**Biocon Limited**, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. **Website: [www.biocon.com](http://www.biocon.com); Follow-us on Twitter: [@bioconlimited](https://twitter.com/bioconlimited)**

**About Biocon Biologics Limited:**

Biocon Biologics Limited, a subsidiary of Biocon Limited, is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world. Building on the four pillars of Patients, People, Partners and Business, Biocon Biologics is committed to transforming healthcare and transforming lives. Biocon Biologics is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Five molecules from Biocon Biologics' portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. With a team of over 4800 people, Biocon Biologics aspires to transform healthcare through affordable innovative solutions as well as impact millions of patients' lives.

**Biocon Biologics on the Web; Website: Follow-us on Twitter: [@BioconBiologics](https://twitter.com/BioconBiologics)**

**Syngene International Limited** (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's 4200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA. Syngene follows an April-March financial year. For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com).